FG 7142: is this validated tool to study anxiety now forgotten? von Horowski, R.

Volltext

Japanese medicine and Berlin: a very special and successful relationship von Horowski, R.

Volltext

The "Madness" of Friedrich Hölderlin: an iatrogenic intoxication von Horowski, R.

Volltext

Classical dopamine agonists von Horowski, R., Löschmann, P.-A.

Volltext

L-DOPA products for continuous dopaminergic stimulation von Horowski, R.

Volltext

A history of dopamine agonists. From the physiology and pharmacology of dopamine to therapies for prolactinomas and Parkinson's disease - a subjective view von Horowski, R

Volltext

High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study von Graf, M, Ecker, D, Horowski, R, Kramer, B, Riederer, P, Gerlach, M, Hager, C, Ludolph, A C, Becker, G, Osterhage, J, Jost, W H, Schrank, B, Stein, C, Kostopulos, P, Lubik, S, Wekwerth, K, Dengler, R, Troeger, M, Wuerz, A, Hoge, A, Schrader, C, Schimke, N, Krampfl, K, Petri, S, Zierz, S, Eger, K, Neudecker, S, Traufeller, K, Sievert, M, Neundörfer, B, Hecht, M

Volltext

Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial ro... von Hofmann, C, Penner, U, Dorow, R, Pertz, H H, Jähnichen, S, Horowski, R, Latté, K P, Palla, D, Schurad, B

Volltext

Anxiogenic, not psychotogenic, properties of the partial inverse benzodiazepine receptor agonist FG 7142 in man von Horowski, R, Dorrow, R

Volltext

P2.146 Receptor proflle of lisuride at monoaminergic receptors contributes to its high efflcacy in Parkinson's disease and Restless Legs Syndrome von Latté, K.P, Horowski, R, Pertz, H.H

Volltext

P2.171 Transdermal lisuride achieves stable plasma levels in Parkinson's disease (PD) von Vacca, L, Stocchi, F, Latté, K.P, Horowski, R

Volltext

P3.175 Transdermal lisuride is effective in Restless Legs Syndrome (RLS) von Beneŝs, H, Kohnen, R, Horowski, R, Latté, K.P, Palla, D

Volltext

2.251 Possible neuroprotective properties of the dopamine agonist lisuride von Horowski, R, Latté, K.P, Kranda, K, Flieger, M

Volltext

2.250 Continuous dopaminergic stimulation (CDS) with lisuride improves the therapy of Parkinson's disease von Horowski, R, Latté, K.P, Palla, D, Wachtel, H, Löschmann, P.A

Volltext

Striatal plasticity and motor learning—importance of circadian rhythms, sleep stages and dreaming von Horowski, R, Beneš, H, Fuxe, K

Volltext

Agonism at 5-HT2B receptors is not a class effect of the ergolines von JÄHNICHEN, Sven, HOROWSKI, Reinhard, PERTZ, Heinz H

Volltext

Schaltenbrand von Horowski, R

Volltext

CNS research in the pharmaceutical industry. A personal view of how innovation could be promoted by clinical pharmacology von Horowski, R

Volltext

1.IS.4.3 Efficacy and safety of transdermal lisuride (LIS) in advanced Parkinson's disease (PD) von Ebersbach, G, Poewe, W, Bojar, M, Martignoni, E, Rascol, O, Reichmann, H, Sampaio, C, Stocchi, F, Tolosa, E, Runge, I, Horowski, R

Volltext

2.249A Efficacy and safety of transdermal lisuride (LIS) in advanced Parkinson's disease (PD) von Ebersbach, G, Poewe, W, Bojar, M, Martignoni, E, Rascol, O, Reichmann, H, Sampaio, C, Stocchi, F, Tolosa, E, Runge, I, Horowski, R

Volltext